Abstract
In 141 postmenopausal node-positive patients with primary breast cancer, routine biochemical markers (alkaline phosphatase, gamma-glutamyl transpeptidase, carcinoembryonic antigen), and chest x-ray, in combination with history and clinical examination, have been performed at 3 monthly intervals for at least 2 years. Sixty one patients relapsed at a median time of 14 months. The recurrence was detected at routine follow-up in 40 (66%) patients. Of these 40 patients, 26 (65%) presented with symptoms, 11 (28%) were asymptomatic but were found to have relapsed on clinical examination, and only 3 (8%) had their relapse diagnosed on the basis of an abnormal chest x-ray. The remaining 21 patients presented early with symptoms. Therefore symptoms and clinical examination accounted for the detection of relapse in 58 of the 61 (95%) patients. Of the patients who had relapsed, 49% (30 of 61) had one or more abnormal markers/chest x-rays prior to relapse, rising to 79% (48 of 61) at the time of relapse. Of 80 patients with no evidence of recurrence, 36% (29) had no marker abnormality recorded, whereas in 64% (51) one or more abnormalities were found. These results suggest that history and examination are the important procedures in follow-up, and that abnormal markers are not always due to metastatic disease and may be misleading.
References
Clark PB, Morris DL: Management of patients after mastectomy. Br Med 282: 2095–2096, 1981
Coombes RC, Chilvers C, Dowsett M, Gazet J-C, Ford HT, Bettelheim R, Gordon C, Smith IE, Zava D, Powles TJ: Adjuvant aminoglutethimide therapy for postmenopausal patients with primary breast cancer: Progress report. Cancer Res (Suppl) 42: 3415–3419, 1982
Coombes RC, Powles TJ, Abbott M, De Rivas L, Ford HT, McCready VR, Neville AM, Gazet J-C: Physical tests for distant metastases in patients with breast cancer. J Roy Soc Med 73: 617–623, 1980
Coombes RC, Powles TJ, Gazet J-C, Nash AG, Ford HT, McKinna A, Neville AM: Assessment of biochemical tests to screen for metastases in patients with breast cancer. Lancet i: 296–299, 1980
Coombes RC, Powles TJ, Gazet J-C, Ford HT, Laurence DJR, Neville AM: Assessment of biochemical markers in breast cancer. Lancet i: 132–134, 1977
Forrest APM, Cant ELM, Roberts MM, Stewart HJ, Sumerling MD, Donaldson AA, Smith AF, Shivas AA: Is the investigation of patients with breast cancer for occult metastatic disease worthwhile? Br J Surg 66: 749–751, 1979
Hayward JL, Carbone PP, Heuson J-C, Kumaoka S, Segaloff A, Rubens RD: Assessment of response to therapy in advanced breast cancer. Cancer 39: 1289–1294, 1977
Hortobagyi GN, Libshitz HI, Seabold JE: Osseous metastases of breast cancer. Cancer 53: 577–582, 1984
Horton J: Follow-up of breast cancer patients. Cancer 53: 790–797, 1984
Hughes LE, Courtney SP: Follow-up of patients with breast cancer. Br Med J 290: 1229–1230, 1985
Perez DJ, Powles TJ, Milan J, Gazet J-C, Ford HT, McCready VR, MacDonald JS, Coombes RC: Detection of breast carcinoma metastases in bone: relative merits of Xrays and skeletal scintigraphy. Lancet ii: 613–616, 1983
Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, Mantel N, McPherson K, Peto J, Smith PG: Design and analysis of randomized clinical trials requiring prolonged observation of each patient II. Analysis and examples. Br J Cancer 35: 1–39, 1977
Tesoro-Tess JD, Valagussa P, Gardani G, Rossi A, Tancini G, Bajetta E, Marchini S, Uslengh C: Usefulness of chest and skeletal survey to assess the time of relapse in breast cancer. Tumori 67: 35–38, 1981
Waalkes TP, Abeloff MD, Ettinger DS, Woo KB, Gehrke CW, Mrochek JE: Multiple biological markers and breast carcinoma: a preliminary study in the detection of recurrent disease after primary therapy. J Surg Oncol 18: 9–19, 1981
Winchester DP, Sener SF, Khandekar JD, Oviedo MA, Cunningham MP, Caprini JA, Burkett FE, Scanlon EF: Symptomatology as an indicator of recurrent or metastatic breast cancer. Cancer 43: 956–960, 1979
Scanlon WF, Oviedo MA, Cunningham MP, Caprini JA, Khandekar JD, Cohen E, Robinson B, Stein E: Preoperative and follow-up procedures on patients with breast cancer. Cancer 46: 977–979, 1980
Valagussa P, Tesoro-Tess JD, Rossi A, Tancini G, Banfi A, Bonadonna G: Adjuvant CMF effect on site of first recurrence and appropriate follow-up intervals, in operable breast cancer with positive axillary nodes. Breast Cancer Res Treat 1: 349–356, 1981
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Mansi, J.L., Earl, H.M., Powles, T.J. et al. Tests for detecting recurrent disease in the follow-up of patients with breast cancer. Breast Cancer Res Tr 11, 249–254 (1988). https://doi.org/10.1007/BF01807283
Issue Date:
DOI: https://doi.org/10.1007/BF01807283